Article
Multidisciplinary Sciences
Tung-Shing Mamie Lih, Mingming Dong, Leslie Mangold, Alan Partin, Hui Zhang
Summary: This study investigated the clinical utility of urinary marker panels composed of urinary glycopeptides and/or urinary prostate-specific antigen (PSA) for distinguishing non-aggressive from aggressive prostate cancer. The multi-marker panels showed clinically meaningful results with area under the curve (AUC) ranging from 0.70 to 0.85.
SCIENTIFIC REPORTS
(2022)
Review
Oncology
Leibo Wang, Wei He, Guanyu Shi, Guoqiang Zhao, Zhuangding Cen, Feng Xu, Wu Tian, Xin Zhao, Chishou Mo
Summary: This study conducted a network meta-analysis to compare the diagnostic value of different urinary markers for prostate cancer. The results showed that Selectmdx and MIPS were the most suitable urine markers for prostate cancer screening and diagnosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Analytical
Heena Tyagi, Emma Daulton, Ayman S. Bannaga, Ramesh P. Arasaradnam, James A. Covington
Summary: Bladder cancer and prostate cancer are commonly diagnosed with invasive techniques, but a non-invasive diagnostic approach using volatile organic compounds (VOCs) shows promise. Analysis of urinary VOC profiles using GC-IMS and GC-TOF-MS can effectively distinguish between BCa and PCa, offering potential for cancer diagnosis.
Review
Oncology
Kit Man Chan, Jonathan M. Gleadle, Michael O'Callaghan, Krasimir Vasilev, Melanie MacGregor
Summary: The review highlights the potential of urinary biosensors for non-invasive prostate cancer detection, but large-scale trials are needed to validate these approaches. Clinical studies have shown good discrimination between prostate cancer patients and controls, but more research is needed to address the ability of these biosensors to differentiate between aggressive and indolent cancer.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Review
Medicine, General & Internal
Na Wang, Shuai Yuan, Cheng Fang, Xiao Hu, Yu-Sen Zhang, Ling-Ling Zhang, Xian-Tao Zeng
Summary: Extracellular vesicles (EVs) are natural nanoparticles secreted by cells in the body and can be used as important markers for disease diagnosis and prognosis. Nanomaterial-based platforms have been innovatively explored for the isolation and detection of EVs from urine, providing higher selectivity and sensitivity. This review focuses on the nanomaterials used in the isolation and detection of urinary EVs, and presents urinary EV-derived biomarkers for prostate cancer diagnosis.
FRONTIERS IN MEDICINE
(2022)
Article
Biochemical Research Methods
Mingming Dong, Tung-Shing Mamie Lih, Naseruddin Hoti, Shao-Yung Chen, Sean Ponce, Alan Partin, Hui Zhang
Summary: The study identified ACPP and CLU in urine, combined with PSA, as potential markers for aggressive prostate cancer detection. The developed PRM assays for urinary glycopeptides showed good repeatability and wide working range, improving discrimination power for aggressive PCa.Combining ACPP, CLU, and serum PSA into a three-signature panel further enhanced the predictive power towards aggressive PCa detection.
JOURNAL OF PROTEOME RESEARCH
(2021)
Article
Biophysics
Meriem Mokni, Amal Tlili, Ghada Attia, Sohayb Khaoulani, Chouki Zerrouki, Asma Omezzine, Ali Othmane, Ali Bouslama, Najla Fourati
Summary: This study reports the design of an electrochemical immunosensor for detecting prostate cancer. The immunosensor was able to selectively detect EN2 in urine and showed comparable results in artificial urine to those obtained in PBS. These findings suggest a potentially promising future for the development of robust and accurate urinary biomarker detection using electrochemical biosensors.
BIOSENSORS & BIOELECTRONICS
(2022)
Article
Oncology
Maria Grazia Maddalone, Marco Oderda, Giulio Mengozzi, Iacopo Gesmundo, Francesco Novelli, Mirella Giovarelli, Paolo Gontero, Sergio Occhipinti
Summary: Urinary zinc levels may serve as an important parameter for diagnosing and predicting prostate cancer. Patients with prostate cancer have lower levels of zinc in their urine, and there is an inverse correlation with tumor stage. Combining zinc with other standard parameters can enhance diagnostic performance, suggesting that urinary zinc may be an early and non-invasive biomarker for prostate cancer.
Review
Biochemistry & Molecular Biology
Sana Kari, Kumar Subramanian, Ilenia Agata Altomonte, Akshaya Murugesan, Olli Yli-Harja, Meenakshisundaram Kandhavelu
Summary: Programmed cell death, particularly apoptosis, plays a crucial role in regulating tissue growth, cell turnover, immune response, and other biological processes. Microscopy allows the identification of different types of cell death based on patterns and events. Biomarkers have been identified to aid in drug development for inducing cell death in cancer cells.
Article
Chemistry, Analytical
Balazs Reider, Eszter Gacsi, Hajnalka Jankovics, Ferenc Vonderviszt, Tibor Szarvas, Andras Guttman, Gabor Jarvas
Summary: This paper describes the development and implementation of a high-throughput capillary electrophoresis-based glycan analysis workflow for urinary PSA, which shows excellent selectivity and high resolution, making it a valuable tool for distinguishing different forms of prostate cancer.
ANALYTICA CHIMICA ACTA
(2021)
Article
Cell Biology
Fang Guo, Bao Zhang, Hao Yang, Yixi Fu, Yaning Wang, Jianming Huang, Mi Cheng, Xiaobo Li, Zhuojian Shen, Li Li, Ping He, Andy Peng Xiang, Shuaiyu Wang, Hongbo Zhang
Summary: The study revealed that the transcriptomes of placentae from EOPE were significantly different from controls, while those from LOPE were not. Conversely, the transcriptomes of peripheral blood from LOPE showed more differences from controls compared to EOPE. Classical biomarkers of pre-eclampsia were specifically expressed in extravillous trophoblast and syncytiotrophoblast, only being upregulated in EOPE. New biomarkers for EOPE and LOPE, such as EBI3, IGF2, ORMDL3, GATA2, and KIR2DL4, were experimentally verified with patient samples.
CELL PROLIFERATION
(2021)
Article
Environmental Sciences
Jeong Weon Choi, Yoon Chae Song, Nam-Yong Cheong, Kiyoung Lee, Sunmi Kim, Kyoung-Mu Lee, Kyunghee Ji, Mi-Yeon Shin, Sungkyoon Kim
Summary: This study investigated the levels and distributions of arsenic species in urine and blood in the Korean population. It found that blood arsenic concentration cannot represent urinary arsenic, but different compositions of urine and blood may reflect distinct information about arsenic exposure. Further investigations on exposure factors and health are needed for low-exposure groups.
ENVIRONMENTAL RESEARCH
(2022)
Review
Cell Biology
Amish Gaur, Luc Rivet, Ethan Mah, Kritleen K. Bawa, Damien Gallagher, Nathan Herrmann, Krista L. Lanctot
Summary: Mild cognitive impairment (MCI) is an early stage of dementia (such as Alzheimer's disease) that is accompanied by neurodegenerative signs. This study evaluated potential fluid biomarkers in MCI and found that elevated levels of NfL and GFAP can be detected in both cerebrospinal fluid (CSF) and peripheral blood. Monitoring these biomarkers may provide important insights into the underlying neurodegenerative processes in MCI.
AGEING RESEARCH REVIEWS
(2023)
Review
Oncology
Samaneh Eickelschulte, Anja Lisa Riediger, Arlou Kristina Angeles, Florian Janke, Stefan Duensing, Holger Sueltmann, Magdalena Goertz
Summary: Prostate cancer, a heterogeneous disease, lacks accurate diagnostic biomarkers such as prostate-specific antigen. Novel tissue and liquid biopsy biomarkers have emerged, providing potential complementary options for the diagnosis of heterogeneous tumors. Current liquid biopsy approaches offer characteristics of tumors, but the spatial heterogeneity of tumors highlights the need for additional diagnostic and prognostic options.
Review
Nutrition & Dietetics
Yingqi Zhang, Chao Lu, Jin Zhang
Summary: Lactoferrin, a major functional protein in human health maintenance, has potential as a biomarker for diseases such as inflammatory bowel disease and Alzheimer's disease. Various methods have been developed for detecting lactoferrin levels. These studies aim to inspire the development of new sensing systems for lactoferrin detection.
Article
Oncology
Bastiaan M. Prive, Peter H. J. Slootbeek, Babette Laarhuis, Samhita Pamidimarri Naga, Maarten J. van Der Doelen, Ludwike W. M. van Kalmthout, Bart de Keizer, Samer Ezziddin, Clemens Kratochwil, Alfred Morgenstern, Frank Bruchertseifer, Marjolijn J. L. Ligtenberg, J. Alfred Witjes, Inge M. van Oort, Martin Gotthardt, Sandra Heskamp, Marcel J. R. Janssen, Winald R. Gerritsen, James Nagarajah, Niven Mehra
Summary: This study found that in mCRPC patients undergoing DDR gene testing and receiving PSMA-RLT treatment, tumors with DDR abnormalities do not necessarily show better treatment responses.
PROSTATE CANCER AND PROSTATIC DISEASES
(2022)
Article
Oncology
Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits, Inge M. van Oort, Winald R. Gerritsen, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Leonie Kroeze, Haiko J. Bloemendal, Niven Mehra
Summary: The study found that almost half of advanced prostate cancer patients receive recommendations for genetically matched therapies, with over 40% of them showing durable responses to the treatment. These findings support the routine referral of selected prostate cancer patients to molecular tumour boards.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Maarten J. van der Doelen, Irma M. Oving, Dirk N. J. Wyndaele, Jean-Paul van Basten, Frederiek Terheggen, Addy C. M. van de Luijtgaarden, Wim J. G. Oyen, W. Dick van Schelven, Franchette van den Berkmortel, Niven Mehra, Marcel J. R. Janssen, Judith B. Prins, Winald R. Gerritsen, Jose A. E. Custers, Inge M. van Oort
Summary: This study evaluated the health-related quality of life, psychological distress, and fatigue in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223. The study found that patients who discontinued radium-223 therapy had worse HR-QoL, psychological distress, and fatigue at baseline and more frequent deterioration over time compared to patients who completed therapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
S. G. Creemers, B. Van Santvoort, F. W. P. J. van den Berkmortel, L. A. Kiemeney, I. M. van Oort, K. K. H. Aben, P. Hamberg
Summary: Participation in multidisciplinary team meetings is associated with a higher likelihood of receiving chemohormonal therapy in patients with metastatic prostate cancer, suggesting that the organizational structure of MDTs aids in the implementation of innovative treatment options.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Oncology
Niven Mehra, Karim Fizazi, Johann S. de Bono, Philippe Barthelemy, Tanya Dorff, Adam Stirling, Jean-Pascal Machiels, Davide Bimbatti, Deepak Kilari, Herlinde Dumez, Consuelo Buttigliero, Inge M. van Oort, Elena Castro, Hsiang-Chun Chen, Nicola Di Santo, Liza DeAnnuntis, Cynthia G. Healy, Giorgio Scagliotti
Summary: This study provides an in-depth analysis of the safety profile of talazoparib in men with metastatic castration-resistant prostate cancer. The most common adverse events include anemia, nausea, decreased appetite, and asthenia. Hematologic adverse events typically occur during the early months of treatment.
Article
Oncology
Gijs P. A. van den Bergh, Malou C. P. Kuppen, Hans M. Westgeest, Niven Mehra, Winald R. Gerritsen, Katja K. H. Aben, Inge M. van Oort, Reindert J. A. van Moorselaar, Diederik M. Somford, Alfonsus J. M. van den Eertwegh, Andre M. Bergman, Alphonsus C. M. van den Bergh, Carin A. Uyl-de Groot
Summary: This real-world population study investigates the incidence and treatment of visceral metastases (VMs) in castration-resistant prostate cancer (CRPC) patients and their survival. The study found that the location of VMs impacts patients' survival and despite an increase in radiological staging, many patients were not screened for VMs at the start of systemic treatment. Routine staging of CRPC patients is necessary.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Medical Laboratory Technology
Denis Horgan, Mario Plebani, Matthias Orth, Elizabeth Macintyre, Stan Jackson, Jonathan A. Lal, France Dube, Marta Kozaric, Birute Tumiene, Roberto Salgado, Jack A. Schalken, Ettore D. Capoluongo, Marta Carnielli
Summary: The background of this debate is the EU's decision to tighten controls on the devices and diagnostics sector, which led to the adoption of a regulation with a schedule for implementation. The recent deferral of implementation deadlines has exposed ongoing challenges in terms of awareness and implementation of the regulation across Europe. There is limited awareness of the In Vitro Diagnostic Regulation (IVDR) and the different national systems involved, which poses risks for patient and consumer access to in vitro diagnostics (IVDs). The proposed solutions so far remain more aspirational than practical.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Urology & Nephrology
Mitchell G. Lawrence, Renea A. Taylor, Georgia B. Cuffe, Lisa S. Ang, Ashlee K. Clark, David L. Goode, Laura H. Porter, Clementine Le Magnen, Nora M. Navone, Jack A. Schalken, Yuzhuo Wang, Wytske M. van Weerden, Eva Corey, John T. Isaacs, Peter S. Nelson, Gail P. Risbridger
Summary: This Perspective article discusses patient-derived xenografts (PDXs) of prostate cancer and their utility in basic and preclinical research. The authors emphasize the need for more diverse and accessible PDX models to reflect patient diversity and study emerging treatment strategies and mechanisms of resistance. Collaboration and data sharing can greatly enhance the use of PDXs in prostate cancer research.
NATURE REVIEWS UROLOGY
(2023)
Article
Oncology
Gerben Lassche, Adriana C. H. van Engen-van Grunsven, Onno van Hooij, Tilly W. Aalders, Jetty A. M. Weijers, Emiliano Cocco, Alexander Drilon, Alexander Hoischen, Kornelia Neveling, Jack A. Schalken, Gerald W. Verhaegh, Carla M. L. van Herpen
Summary: The use of anticancer drugs targeting specific molecular tumor characteristics is increasing, but selecting patients to benefit from these treatments remains challenging. Organoid cultures have been proposed as a suitable method to test drug responses in vitro. This study presents a case of secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion and corresponding organoid cultures. The cultures initially responded to TRK targeting therapy, but later developed resistance. This case highlights the advancements in precision oncology and the limitations of using organoids in predicting treatment response.
Article
Oncology
Babette I. Laarhuis, Marcel J. R. Janssen, Michiel Simons, Ludwike W. M. van Kalmthout, Maarten J. van der Doelen, Steffie M. B. Peters, Harm Westdorp, Inge M. van Oort, Geert Litjens, Martin Gotthardt, James Nagarajah, Niven Mehra, Bastiaan M. Prive
Summary: This study aimed to understand the reasons behind the failure of prostate specific membrane antigen radioligand therapy (PSMA-RLT) by evaluating the correlation between PSMA expression on immunohistochemistry (IHC) and PSMA uptake on PET/CT imaging. Additionally, the relationship between PSMA expression, Ki67 expression, and the therapeutic outcome of PSMA-RLT was assessed.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Biochemistry & Molecular Biology
Levi Groen, Iris Kloots, David Englert, Kelly Seto, Lana Estafanos, Paul Smith, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken
Summary: The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is well recognized. The earliest methods for enriching CTCs relied on antibody-based positive selection, but it has limitations in capturing the heterogeneity of cancer. This study used the recently FDA-approved Parsortix (R) technology to enrich CTCs from prostate cancer patients and found that targeted CTC transcriptome profiling may be predictive of therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Peter H. J. Slootbeek, Iris S. H. Kloots, Inge M. van Oort, Leonie I. Kroeze, Jack A. Schalken, Haiko J. Bloemendal, Niven Mehra
Summary: Patients with mCRPC and HRRm can benefit from both PlCh and PARPi, with PlCh inducing less cross-resistance. The order of agents in treatment influenced the PFS, with shorter PFS after PARPi when administered second and shorter PFS after PlCh when administered first. More than 40% of the patients were sensitive to a subsequent HRR-targeting agent. Understanding resistance mechanisms is crucial for determining optimal treatment sequence in HRRm mCRPC patients.
Review
Medical Laboratory Technology
Peter H. J. Slootbeek, Sofie H. Tolmeijer, Niven Mehra, Jack A. Schalken
Summary: The treatment of metastatic castration-resistant prostate cancer has been transformed by precision oncology, aiming to match targeted therapies with tumor genotypes through ctDNA sequencing to monitor treatment response and resistance mechanisms for improved outcomes.
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
(2023)
Article
Urology & Nephrology
Niven Mehra, Iris Kloots, Michiel Vlaming, Shafak Aluwini, Els Dewulf, Daniela E. Oprea-Lager, Henk van der Poel, Herman Stoevelaar, Derya Yakar, Chris H. Bangma, Elise Bekers, Roderick van den Bergh, Andries M. Bergman, Franchette van den Berkmortel, Steve Boudewijns, Winand N. M. Dinjens, Jurgen Futterer, Tom van der Hulle, Guido Jenster, Leonie I. Kroeze, Michel van Kruchten, Geert van Leenders, Pim J. van Leeuwen, Wendy W. J. de Leng, R. Jeroen A. van Moorselaar, Walter Noordzij, Rogier A. Oldenburg, Inge M. van Oort, Irma Oving, Jack A. Schalken, Ivo G. Schoots, Ed Schuuring, Robert J. Smeenk, Ben G. L. Vanneste, Erik Vegt, Andre N. Vis, Kim de Vries, Peter-Paul M. Willemse, Maurits Wondergem, Margreet Ausems
Summary: A group of Dutch specialists discussed the use of germline and tumour genetic testing in prostate cancer (PCa) patients, indication of these tests (which patients and when), and impact of these tests on the management and treatment of PCa.
EUROPEAN UROLOGY OPEN SCIENCE
(2023)
Meeting Abstract
Urology & Nephrology
Whitney Stanton, E. David Crawford, Paul Arangua, Joshua Romero, Francisco G. La Rosa, Adrie van Bokhoven, M. Scott Lucia, Paul Maroni, Wendy Poage, Jack Schalken, Fernando Kim, Jack Groskopf, Priya Werahera
JOURNAL OF UROLOGY
(2022)